Istradefylline

Drug Profile

Istradefylline

Alternative Names: KW-6002; Nouriast

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Kyowa Hakko
  • Developer Kyowa Hakko; Kyowa Hakko Kirin
  • Class Antidepressants; Antiparkinsonians; Neuroprotectants; Purines; Small molecules
  • Mechanism of Action Adenosine A2 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Marketed Parkinson's disease
  • Phase I Drug abuse
  • Discontinued Major depressive disorder; Restless legs syndrome

Most Recent Events

  • 13 Dec 2016 Top-line efficacy and adverse events data from a phase III trial in parkinson's disease released by Kyowa Hakko Kirin
  • 01 Oct 2016 Kyowa Hakko Kirin Pharma completes a phase-III clinical trials in Parkinson's disease (Adjunctive treatment) in USA, Canada, Czech Republic, Germany, Italy, Poland, Serbia, Israel (PO) (NCT01968031)
  • 18 Aug 2016 Kyowa Hakko Kirin Pharma terminates a phase I trial in Healthy volunteers (recreational drug users) in USA due to difficulty in enrolment of subjects (PO) (NCT02609477)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top